September 12, 2023 03:29 PM EDT

'A done deal': FDA advisory committee votes unanimously against efficacy data for OTC nasal decongestant

Nicole DeFeudis

Editor

Members of an FDA advisory committee on Tuesday voted unanimously against the efficacy of an over-the-counter nasal decongestant that’s been on the US market for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'A done deal': FDA advisory committee votes unanimously against efficacy data for OTC nasal decongestant

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis highlights overall M&A track record following MorphoSys impairment

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

'A done deal': FDA ad­vi­so­ry com­mit­tee votes unan­i­mous­ly against ef­fi­ca­cy da­ta for OTC nasal de­con­ges­tant

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

'A done deal': FDA advisory committee votes unanimously against efficacy data for OTC nasal decongestant